Eric M Dube
CIK 1763494 · CHIEF EXECUTIVE OFFICER · last filed 2026-09-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TVTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVTX | CHIEF EXECUTIVE OFFICER | 465,054 | $49.60 | $23.07M | -$46.31M | 32 | 2026-09-17 |
| OnKure Therapeutics, Inc. (RPHM) Delisted | Director | — | $18.20 | — | $0 | 2 | 2023-06-08 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Chief Executive Officer | 96,260 | — | — | -$317.4K | 5 | 2020-09-22 |
Recent Filings · Page 6 of 7
61 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-02-05 | TVTX | Grant (A) | +17,500 | $0 | EDGAR |
| 2021-02-03 | TVTX | Sell (S) | −2,406 | -$69.6K | EDGAR |
| 2021-02-02 | TVTX | Mixed | +6,266 | -$261.3K | EDGAR |
| 2021-01-28 | TVTX | Grant (A) | — | $0 | EDGAR |
| 2021-01-25 | TVTX | Grant (A) | +57,260 | $0 | EDGAR |
| 2021-01-07 | TVTX | Sell (S) | −6,876 | -$184.5K | EDGAR |
| 2020-09-22 | Travere Therapeutics, Inc. (RTRX) Delisted | Mixed | +17,195 | -$208.3K | EDGAR |
| 2020-01-31 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2020-01-08 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −7,500 | -$109.0K | EDGAR |
| 2019-05-10 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.